C. Stoffregen

951 total citations
41 papers, 678 citations indexed

About

C. Stoffregen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, C. Stoffregen has authored 41 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in C. Stoffregen's work include Colorectal Cancer Treatments and Studies (7 papers), Advanced Breast Cancer Therapies (6 papers) and Pancreatic function and diabetes (5 papers). C. Stoffregen is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Advanced Breast Cancer Therapies (6 papers) and Pancreatic function and diabetes (5 papers). C. Stoffregen collaborates with scholars based in Germany, United States and Italy. C. Stoffregen's co-authors include U. Ohnmacht, Norman Rieger, Christian Manegold, Jürgen R. Fischer, Marius Žemaitis, Harald Lahm, Peter E. Huber, Marc Bischof, Volker Heinemann and Ralf Wilkowski and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

C. Stoffregen

40 papers receiving 667 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Stoffregen Germany 15 264 246 201 181 135 41 678
T. Geldart United Kingdom 15 293 1.1× 178 0.7× 202 1.0× 211 1.2× 53 0.4× 40 642
George Philips United States 15 386 1.5× 254 1.0× 301 1.5× 311 1.7× 117 0.9× 41 916
Claudia Caserta Italy 19 513 1.9× 318 1.3× 156 0.8× 350 1.9× 118 0.9× 50 949
Chad A. Barnes United States 14 324 1.2× 208 0.8× 127 0.6× 125 0.7× 198 1.5× 20 552
Fabio A. Schutz United States 11 299 1.1× 381 1.5× 263 1.3× 177 1.0× 136 1.0× 30 685
Alberto Comino Italy 11 430 1.6× 85 0.3× 319 1.6× 140 0.8× 118 0.9× 20 704
Mona Ridderheim Sweden 13 307 1.2× 116 0.5× 197 1.0× 137 0.8× 109 0.8× 26 825
Jean Pierre Delord France 13 514 1.9× 185 0.8× 233 1.2× 87 0.5× 57 0.4× 20 792
Joseph T. Ruggiero United States 6 422 1.6× 151 0.6× 226 1.1× 98 0.5× 241 1.8× 8 709
Pablo Gajate Spain 15 329 1.2× 102 0.4× 146 0.7× 140 0.8× 42 0.3× 51 601

Countries citing papers authored by C. Stoffregen

Since Specialization
Citations

This map shows the geographic impact of C. Stoffregen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Stoffregen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Stoffregen more than expected).

Fields of papers citing papers by C. Stoffregen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Stoffregen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Stoffregen. The network helps show where C. Stoffregen may publish in the future.

Co-authorship network of co-authors of C. Stoffregen

This figure shows the co-authorship network connecting the top 25 collaborators of C. Stoffregen. A scholar is included among the top collaborators of C. Stoffregen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Stoffregen. C. Stoffregen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goetz, Matthew P., Miguel Martín, Eriko Tokunaga, et al.. (2020). Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer. The Oncologist. 25(9). e1346–e1354. 35 indexed citations
2.
Kaufman, Peter A., Masakazu Toi, Patrick Neven, et al.. (2019). Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. The Oncologist. 25(2). e243–e251. 51 indexed citations
3.
Stoffregen, C., et al.. (2016). Reduced folate and serum vitamin metabolites in patients with rectal carcinoma. Anti-Cancer Drugs. 27(5). 439–446. 7 indexed citations
4.
Wick, Wolfgang, Joachim P. Steinbach, Michael Platten, et al.. (2013). Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology. 15(10). 1405–1412. 39 indexed citations
5.
6.
Rampling, R., Marc Sanson, T. Gorlia, et al.. (2012). A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro-Oncology. 14(3). 344–350. 14 indexed citations
7.
8.
9.
10.
Paulussen, Michael, et al.. (2006). Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anti-Cancer Drugs. 17(7). 859–864. 31 indexed citations
11.
Bischof, Marc, Amir Abdollahi, Ping Gong, et al.. (2004). Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. International Journal of Radiation Oncology*Biology*Physics. 60(4). 1220–1232. 50 indexed citations
12.
Bischof, Marc, et al.. (2003). Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases. International Journal of Radiation Oncology*Biology*Physics. 57(1). 289–292. 24 indexed citations
13.
Stemmler, Hans‐Joachim, P Stieber, Andreas Schalhorn, et al.. (2003). Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin?. Oncology Research and Treatment. 26(5). 462–467. 57 indexed citations
14.
Wilkowski, Ralf, Martin Thoma, Volker Heinemann, et al.. (2003). Radiochemotherapie mit Gemcitabin und Cisplatin bei Pankreaskarzinom – durchführbar und effektiv. Strahlentherapie und Onkologie. 179(2). 78–86. 25 indexed citations
15.
Wilkowski, Ralf, Volker Heinemann, & C. Stoffregen. (2001). Gemcitabine (Gemzar<sup>&reg;</sup>) and Radiotherapy - Is It Feasible?. Frontiers of radiation therapy and oncology. 37. 78–83. 1 indexed citations
16.
Schlottmann, Klaus, et al.. (2001). A phase I study of irinotecan (I), gemcitabine (G), and 5-fluorouracil (5-FU) in patients with advanced gastrointestinal cancers. European Journal of Cancer. 37. S289–S289. 1 indexed citations
17.
Arendt, Thomas, et al.. (1997). Santoriniʼs duct - risk factor for acute pancreatitis or protective morphologic variant? Experiments in rabbits. European Journal of Gastroenterology & Hepatology. 9(6). 569–573. 12 indexed citations
18.
Stoffregen, C., et al.. (1996). Weekly High-Dose 5-Fluorouracil 24-Hour Infusion and Intermediate-Dose Folinic Acid Bolus in Metastatic Colorectal Cancer. Oncology Research and Treatment. 19(5). 410–414. 7 indexed citations
19.
Arendt, Thomas, et al.. (1996). Does high pancreatic duct pressure compromise the duct mucosal barrier function to pancreatic exocrine proteins?. Apmis. 104(7-8). 615–622. 2 indexed citations
20.
Timmermann, W., et al.. (1990). Development and perspectives of experimental pancreas transplantation in the Rat. Microsurgery. 11(2). 133–139. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. Geldart Breakdown of academic impact, for papers by George Philips Breakdown of academic impact, for papers by Claudia Caserta Breakdown of academic impact, for papers by Chad A. Barnes Breakdown of academic impact, for papers by Fabio A. Schutz Breakdown of academic impact, for papers by Alberto Comino Breakdown of academic impact, for papers by Mona Ridderheim Breakdown of academic impact, for papers by Jean Pierre Delord Breakdown of academic impact, for papers by Joseph T. Ruggiero Breakdown of academic impact, for papers by Pablo Gajate
Rankless by CCL
2026